These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3414786)

  • 21. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
    Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
    Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The SCID-hu myeloma model.
    Epstein J; Yaccoby S
    Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically engineered myeloma cell vaccine.
    Hao S; Chan T; Xiang J
    Methods Mol Med; 2005; 113():235-44. PubMed ID: 15968107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
    Bueno C; Lopes LF; Greaves M; Menendez P
    Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
    [No Abstract]   [Full Text] [Related]  

  • 26. Tenfold increased incidence of spontaneous multiple myeloma in long-term immunosuppressed aging C57BL/KaLwRij mice.
    Radl J; Van Arkel C; Hopstaken CM; HogenEsch H
    Clin Immunol Immunopathol; 1996 May; 79(2):155-62. PubMed ID: 8620621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
    Valeriote F; Grates H
    J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
    Vanderkerken K; De Leenheer E; Shipman C; Asosingh K; Willems A; Van Camp B; Croucher P
    Cancer Res; 2003 Jan; 63(2):287-9. PubMed ID: 12543775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
    Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
    Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New experimental model of multiple myeloma.
    Telegin GB; Kalinina AR; Ponomarenko NA; Ovsepyan AA; Smirnov SV; Tsybenko VV; Homeriki SG
    Bull Exp Biol Med; 2001 Jun; 131(6):609-12. PubMed ID: 11586419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.
    De Bruyne E; Andersen TL; De Raeve H; Van Valckenborgh E; Caers J; Van Camp B; Delaissé JM; Van Riet I; Vanderkerken K
    Leukemia; 2006 Oct; 20(10):1870-9. PubMed ID: 16900214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro cloning and chemosensitivity of human myeloma stem cells.
    Salmon SE
    Clin Haematol; 1982 Feb; 11(1):47-63. PubMed ID: 6176384
    [No Abstract]   [Full Text] [Related]  

  • 33. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Various features of the in vivo replication of the murine myeloma cell line X63 Ag8.6.5.3. Preliminary report].
    Aguilar Setién A; Ruiz Gómez MT; Kretschmer R
    Salud Publica Mex; 1985; 27(3):199-202. PubMed ID: 4049116
    [No Abstract]   [Full Text] [Related]  

  • 35. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model.
    Ashihara E; Kawata E; Nakagawa Y; Shimazaski C; Kuroda J; Taniguchi K; Uchiyama H; Tanaka R; Yokota A; Takeuchi M; Kamitsuji Y; Inaba T; Taniwaki M; Kimura S; Maekawa T
    Clin Cancer Res; 2009 Apr; 15(8):2731-8. PubMed ID: 19351774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunotherapy of mice bearing myeloma and EL4 leukemia].
    Kitasato M
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):958-65. PubMed ID: 2447213
    [No Abstract]   [Full Text] [Related]  

  • 37. Multiple myeloma and related disorders. Lessons from an animal model.
    Radl J
    Pathol Biol (Paris); 1999 Feb; 47(2):109-14. PubMed ID: 10192877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Nucleic acid hybridization analysis of the regulatory effect of a cytoplasmic factor on the malignancy of myeloma cells. I. Beta-globin gene expression].
    Wang ZQ; Zhang JB; Chen KQ; Zhang SF; Shen Y; Zhang LY; Yuan J; Xue SP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1987 Oct; 9(5):339-45. PubMed ID: 2968857
    [No Abstract]   [Full Text] [Related]  

  • 39. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
    Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
    Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Establishment of a multiple myeloma local tumor model in mice].
    Liu Y; Zhou MY; Meng WT; Xu CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):647-51. PubMed ID: 20561420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.